Napabucasin
- Generic Name
- Napabucasin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H8O4
- CAS Number
- 83280-65-3
- Unique Ingredient Identifier
- Z1HHM49K7O
- Background
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04299880
- Locations
- 🇯🇵
Kyorin University Hospital, Tokyo, Japan
🇺🇸Maine Center for Cancer Medicine, Scarborough, Maine, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03525405
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- 1Globe Health Institute LLC
- Target Recruit Count
- 668
- Registration Number
- NCT03522649
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03411122
- Locations
- 🇺🇸
Accel Research Sites, DeLand, Florida, United States
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1134
- Registration Number
- NCT02993731
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Montefiore Cancer Center, Bronx, New York, United States
Special Combination of BBI608 and Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Takayuki Yoshino
- Target Recruit Count
- 55
- Registration Number
- NCT02851004
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02826161
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1253
- Registration Number
- NCT02753127
- Locations
- 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸Dana Farber, Boston, Massachusetts, United States
🇨🇦University of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.